EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report Database

Yuko Kanbayashi, Risa Morioka, Keiko Hosohata

Clinical Drug Investigation · 2025

DOI: 10.1007/s40261-025-01490-3 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Drug Investigation, 2025. Verfasst von Yuko Kanbayashi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Evaluation for Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 7-2-1 Kami-Ohno, Himeji, Hyogo, 670…. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Camptothecin, Lung Diseases, Trastuzumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: This study was conducted to examine disproportionality, times to onset, incidence rates, and outcomes of trastuzumab deruxtecan-associated pulmonary adverse events (AEs) using the Japanese Adverse Drug Event Report database. METHODS: We analyzed data for the period from April 2004 to December 2024. Data on pulmonary AEs were extracted, and the relative disproportionality of AEs was estimated using reporting odds ratios (RORs). RESULTS: Of the 3,221,393 reports analyzed, we identified 1561 reports of AEs associated with trastuzumab deruxtecan, including 505 pulmonary AEs. Only 474 reports were identified as signal-positive: interstitial lung disease, pulmonary toxicity, pneumonitis, and Pneumocystis jirovecii pneumonia. Among these, interstitial lung disease was the most frequently reported (26.6%) and included several fatal cases. Histograms of median times to onset for the four detected pulmonary AE signals showed that AEs occurred at a median of 7-27.5 days after trastuzumab deruxtecan administration. Weibull distributions showed that interstitial lung disease occurred early after administration (early failure type), but pulmonary toxicity occurred constantly throughout the exposure period (random failure type). CONCLUSIONS: We focused on pulmonary AEs associated with trastuzumab deruxtecan as postmarketing AEs. Serious outcomes can arise after trastuzumab deruxtecan administration. Patients should be monitored for signs of onset of these AEs not only at the start of administration but also over an extended period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsCamptothecinLung DiseasesTrastuzumabImmunoconjugatesAdultAgedFemaleHumansMaleMiddle AgedDatabases, FactualJapanLung Diseases, Interstitial

Substanzen

CamptothecinTrastuzumabtrastuzumab deruxtecanImmunoconjugates

Autor:innen und Institutionen

  • Department of Evaluation for Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 7-2-1 Kami-Ohno, Himeji, Hyogo, 670-8524, Japan.
  • Department of Drug Evaluation and Informatics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 7-2-1 Kami-Ohno, Himeji, Hyogo, 670-8524, Japan.
  • Department of Drug Evaluation and Informatics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 7-2-1 Kami-Ohno, Himeji, Hyogo, 670-8524, Japan. hosohata@gm.himeji-du.ac.jp.

Zitieren

APA

Kanbayashi, Y., Morioka, R., & Hosohata, K. (2025). Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report Database. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01490-3

Vancouver

Kanbayashi Y, Morioka R, Hosohata K. Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report Database. Clinical Drug Investigation. 2025. doi:10.1007/s40261-025-01490-3

BibTeX
@article{Kanbayashi2025,
  author = {Kanbayashi, Yuko and Morioka, Risa and Hosohata, Keiko},
  title = {Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report Database},
  journal = {Clinical Drug Investigation},
  year = {2025},
  doi = {10.1007/s40261-025-01490-3}
}
Kostenlos starten →